Literature DB >> 7037548

Hydergine in senile mental impairment.

D M Loew, C Weil.   

Abstract

Among gerontopsychiatric drugs, Hydergine is pharmacologically characterized by agonist action at central dopamine and serotonin receptors. This review presents a summary of the results obtained with Hydergine in numerous controlled trials in patients with senile mental impairment. Assessment was carried out by means of a rating scale (mainly the Sandoz Clinical Assessment Geriatric, or SCAG, scale), psychometric tests (e.g. the Nuremberg Geriatric Inventory, or NGI), and the EEG. Hydergine also lowers serum prolactin, though a correlation with clinical improvement has not been established as yet. In the discussion, the need for objective, measurable and precise indicators in gerontopsychiatry is stressed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7037548     DOI: 10.1159/000212511

Source DB:  PubMed          Journal:  Gerontology        ISSN: 0304-324X            Impact factor:   5.140


  4 in total

1.  Senile dementia of the Alzheimer type treated with aniracetam: a new nootropic agent.

Authors:  L B Sourander; R Portin; P Mölsä; A Lahdes; U K Rinne
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 2.  Co-dergocrine mesylate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in age-related cognitive decline.

Authors:  A N Wadworth; P Chrisp
Journal:  Drugs Aging       Date:  1992 May-Jun       Impact factor: 3.923

3.  Steady state bioavailability of a new oral formulation of Hydergine in geriatric patients.

Authors:  F Sörgel; E Abisch; H J Dennler; E Lang
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  Biochemical, behavioural, and endocrine effects of CK 204-933, a novel 8 beta-ergolene.

Authors:  R Markstein; A Enz; J M Vigouret; A Jaton; A Closse; U Briner; P Gull
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.